Online citations, reference lists, and bibliographies.
← Back to Search

Genomic Copy Number Alterations In 33 Malignant Peritoneal Mesothelioma Analyzed By Comparative Genomic Hybridization Array.

P. Chirac, D. Maillet, F. Leprêtre, Sylvie Isaac, O. Gléhen, M. Figeac, L. Villeneuve, J. Péron, F. Gibson, F. Galateau-Sallé, François-Noël Gilly, M. Brevet
Published 2016 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Malignant peritoneal mesotheliomas (MPM) are rare, accounting for approximately 8% of cases of mesothelioma in France. We performed comparative genomic hybridization (CGH) on frozen MPM samples using the Agilent Human Genome CGH 180 K array. Samples were taken from a total of 33 French patients, comprising 20 men and 13 women with a mean (range) age of 58.4 (17-76) years. Asbestos exposure was reported in 8 patients (24.2%). Median (range) overall survival (OS) was 39 (0-119) months. CGH analysis demonstrated the presence of chromosomal instability in patients with MPM, with a genomic pattern that was similar to that described for pleural mesothelioma, including the loss of chromosomal regions 3p21, 9p21, and 22q12. In addition, novel genomic copy number alterations were identified, including the 15q26.2 region and the 8p11.22 region. Median OS was associated with a low peritoneal cancer index (P=.011), epithelioid subtype (P=.038), and a low number of genomic aberrations (P=.015), all of which constitute good prognostic factors for MPM. Our results provide new insights into the genetic and genomic background of MPM. Although pleural and peritoneal mesotheliomas have different risk factors, different therapeutics, and different prognosis; these data provide support to combine pleural and peritoneal mesothelioma in same clinical assays.
This paper references
Epidemiology of peritoneal mesothelioma: a review.
P. Boffetta (2007)
BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma
H. Alakus (2015)
Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study
C. Brigand (2006)
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH
P. M. Lindholm (2007)
COUP‐TFII in pancreatic adenocarcinoma: Clinical implication for patient survival and tumor progression
S. Polvani (2014)
Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies
C. Chia (2015)
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas
S. Chiosea (2008)
Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma
S. S. Murthy (1999)
Germline BAP1 mutations predispose to malignant mesothelioma
J. Testa (2011)
Peritoneal mesothelioma: a review.
A. Bridda (2007)
The expression pattern of β‐catenin in mesothelial proliferative lesions and its diagnostic utilities
Yiran Dai (2005)
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.
D. Jean (2011)
Characterization of a complex chromosome aberration in two cases of peritoneal mesothelioma arising primarily in the hernial sac
Gabriella Serio (2009)
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
Matthew J Bott (2011)
[The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists].
L. Villeneuve (2014)
Malignant Peritoneal Mesothelioma in an Adolescent Male With BAP1 Deletion
Steve Taylor (2015)
Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis.
P. Jacquet (1996)
High-resolution genome-wide analysis identified recurrent genetic alterations in NK/T-cell lymphoma, nasal type, which are associated with disease progression
Lin Sun (2014)
Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32
T. Taniguchi (2007)
Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum.
H. Nemoto (2012)
[The French mesothelioma network from 1998 to 2013].
F. Galateau-Sallé (2014)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Q. Chu (2009)
Waved aCGH: to smooth or not to smooth
F. Lepretre (2010)
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors
Shoshana J. Weiner (2008)
Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.
J. Barrow (2011)
VEGF-B promotes cancer metastasis through a VEGF-A–independent mechanism and serves as a marker of poor prognosis for cancer patients
Xiaojuan Yang (2015)
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
P. Illei (2003)
Human cyritestin genes (CYRN1 and CYRN2) are non-functional.
P. Grzmil (2001)
Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Lele Song (2015)
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
Mésothéliome : les dispositifs en place en France « le réseau mésothéliome » 1998–2013
F. Galateau-Sallé (2014)
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
E. Van Cutsem (2012)
Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group.
A. Husain (2013)
Sarcomatoid mesothelioma: a clinical–pathologic correlation of 326 cases
S. Klebe (2010)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors
Q. Chu (2009)
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
Rhonda L Harmon (2005)
p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos.
P. Andujar (2010)
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guangwu Guo (2015)
Réseau RENAPE : vers une nouvelle organisation des soins pour le traitement des tumeurs rares du péritoine. Description du réseau et rôle des pathologistes
L. Villeneuve (2014)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma.
A. Sandberg (2001)
Inhibition of Wnt-1 Signaling Induces Apoptosis in β-Catenin-Deficient Mesothelioma Cells
L. You (2004)
Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases
M. Krismann (2002)
The many ways of Wnt in cancer.
P. Polakis (2007)
Disease implications of the Hippo/YAP pathway.
Steven W Plouffe (2015)
Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.
Geula Klorin (2013)

This paper is referenced by
Integrated Multi-omics Molecular Subtyping Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma
Raunak Shrestha (2019)
Analyzing biological and molecular characteristics and genomic damage induced by exposure to asbestos
D. Ospina (2019)
Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma
S. Brich (2019)
Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma
Raunak Shrestha (2020)
Genomic Profiling of Malignant Peritoneal Mesothelioma Reveals Recurrent Alterations in Epigenetic Regulatory Genes BAP1, SETD2, and DDX3X
N. Joseph (2017)
Impact d’un réseau national sur la prise en charge des tumeurs rares du péritoine
L. Villeneuve (2017)
Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma
R. Sciarrillo (2019)
BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas
N. Leblay (2017)
Molecular characterization of diffuse malignant peritoneal mesothelioma
Y. Hung (2020)
Tumors of peritoneum. Treatment algorithms
D. V. Sidorov (2020)
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology
K. Sundling (2018)
Well-Differentiated Papillary Mesothelioma of the Peritoneum is Genetically Distinct from Malignant Mesothelioma
Raunak Shrestha (2019)
Cell Signaling and Epigenetic Mechanisms in Mesothelioma
B. Mossman (2017)
Health impact of exposure to asbestos in polluted area of Southern Italy
L. Vimercati (2019)
Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Béatrice Vanbervliet-Defrance (2019)
Dysregulated Expression of the MicroRNA miR‐137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma
T. G. Johnson (2018)
Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives
S. Boussios (2018)
The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
L. Villeneuve (2017)
BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
Computational prioritization of cancer driver genes for precision oncology
Raunak Shrestha (2018)
BAP1 Loss Predicts Therapeutic Vulnerability in Malignant Peritoneal Mesothelioma
Raunak Shrestha (2018)
Pulmonary Malignancies (2): Mesothelioma—What Are the Roles of Genetic Factors in the Pathogenesis of Mesothelioma?
T. Nakano (2018)
Genomics and Epigenetics of Malignant Mesothelioma
Adam P Sage (2018)
Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array
G. Serio (2017)
CMAR_A_205723 4997..5012
Diana Ospina (2019)
Registries and Collaborative Groups in Peritoneal Surface Oncology
A. Bhatt (2018)
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
D. Chapel (2019)
Semantic Scholar Logo Some data provided by SemanticScholar